Biogen’s oral medication Zurzuvae (zuranolone) has been approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of moderate to severe postnatal depression in adults following childbirth. This marks the first oral treatment for the condition approved in the UK .
Zurzuvae is a neuroactive steroid that enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA), which is thought to exert antidepressant effects by enhancing GABAergic inhibition. The medication is taken daily for a 14-day course and has shown to provide rapid improvements in depressive symptoms as early as Day 3, with sustained effects up to Day 45 in clinical trials .
The approval of Zurzuvae in the UK follows its earlier approval by the U.S. Food and Drug Administration (FDA) in 2023. Developed by Sage Therapeutics in partnership with Biogen, the medication offers a convenient oral alternative to the previously available intravenous treatment, brexanolone (Zulresso), which requires administration in a healthcare setting.
The MHRA’s decision is expected to improve access to effective treatment for women experiencing postpartum depression, a condition that affects a significant number of new mothers and can have profound effects on both maternal and infant health.
Biogen has not yet announced the pricing or availability details for Zurzuvae in the UK market.
YOU MAY ALSO LIKE
New Oklahoma Clinic Offers Support for Postpartum Depression
Postpartum Depression: Signs, Risks, and Treatment
Reunion’s RE104 Shows Rapid Relief for Postpartum Depression
